AAL vs CURI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

AAL

46.9
AI Score
VS
AAL Wins

CURI

35.2
AI Score

Investment Advisor Scores

AAL

47score
Recommendation
HOLD

CURI

35score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AAL CURI Winner
Revenue 46.98B 38.41M AAL
Net Income -580.00M 7.55M CURI
Net Margin -1.2% 19.7% CURI
Operating Income 521.00M 7.64M AAL
ROE 13.7% 18.2% CURI
ROA -0.9% 11.2% CURI
Total Assets 65.02B 67.47M AAL
Cash 1.12B 5.38M AAL
Current Ratio 0.53 0.78 CURI

Relative Price Performance (Last 90 Days)

AAL 1M: +11.8% · 3M: -5.5% CURI 1M: -13.9% · 3M: -13.9%

Current Technical Phase

AAL

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 62

RSI (14): 62.3 · Price: $14.11

CURI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 35

RSI (14): 35.2 · Price: $2.41

Fundamentals Snapshot

Metric AAL CURI
Market Cap — —
Forward P/E 15.2 7.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.2% 0.2%
Gross Margin 0.2% 0.6%
Operating Margin 0.0% 0.4%
EPS -0.73 0.00
Dividend Yield — 0.13%

Frequently Asked Questions

Based on our detailed analysis, AAL is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.